Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 248

1.
2.

Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.

Goenka A, Magsanoc JM, Pei X, Schechter M, Kollmeier M, Cox B, Scardino PT, Eastham JA, Zelefsky MJ.

Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):112-8. doi: 10.1016/j.ijrobp.2011.10.077. Epub 2012 Jan 31.

PMID:
22300563
3.

Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes.

Chen CP, Weinberg V, Shinohara K, Roach M 3rd, Nash M, Gottschalk A, Chang AJ, Hsu IC.

Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):324-9. doi: 10.1016/j.ijrobp.2013.01.027. Epub 2013 Mar 6.

PMID:
23474112
4.

Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31.

Souhami L, Bae K, Pilepich M, Sandler H.

Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1301-6. doi: 10.1016/j.ijrobp.2009.10.007. Epub 2010 Mar 29.

PMID:
20356687
5.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
6.
7.

A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.

Armstrong JG, Gillham CM, Dunne MT, Fitzpatrick DA, Finn MA, Cannon ME, Taylor JC, O'Shea CM, Buckney SJ, Thirion PG.

Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):35-45. doi: 10.1016/j.ijrobp.2010.04.065. Epub 2010 Aug 25.

PMID:
20797824
8.

Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.

Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):15-23.

PMID:
15337535
9.

(IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy.

Choo R, Hruby G, Hong J, Bahk E, Hong E, Danjoux C, Morton G, DeBoer G.

Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):269-76.

PMID:
12023129
10.

Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.

Shipley WU, Desilvio M, Pilepich MV, Roach M 3rd, Wolkov HB, Sause WT, Rubin P, Lawton CA.

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1162-7. Epub 2006 Jan 19. Erratum in: Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):313.

PMID:
16427211
12.

Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.

Lee HM, Solan MJ, Lupinacci P, Gomella LG, Valicenti RK.

Urology. 2004 Jul;64(1):84-9.

PMID:
15245941
13.

Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.

Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.

Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):415-9.

PMID:
15667961
14.

Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.

Shipley WU, Lu JD, Pilepich MV, Heydon K, Roach M, Wolkov HB, Sause WT, Rubin P, Lawton CA, Machtay M.

Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1302-10.

PMID:
12459350
15.

Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.

Lee HK, Adams MT, Motta J.

Brachytherapy. 2008 Jan-Mar;7(1):17-21. doi: 10.1016/j.brachy.2007.11.002. Epub 2008 Jan 16.

PMID:
18201939
16.

Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.

D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH.

J Natl Cancer Inst. 2004 Apr 7;96(7):509-15.

PMID:
15069112
17.

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.

Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D.

J Urol. 2004 Mar;171(3):1141-7.

PMID:
14767288
18.

Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.

Ray ME, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Zelefsky MJ, Zietman AL, Kuban DA.

Urology. 2006 Dec;68(6):1257-62. Epub 2006 Dec 4.

PMID:
17141830
19.

Survival benefit for early hormone ablation in biochemically recurrent prostate cancer.

Tenenholz TC, Shields C, Ramesh VR, Tercilla O, Hagan MP.

Urol Oncol. 2007 Mar-Apr;25(2):101-9.

PMID:
17349523
20.

Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.

Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, Cheung P, Pearse M.

Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):983-9. doi: 10.1016/j.ijrobp.2008.12.049. Epub 2009 May 4.

PMID:
19409726

Supplemental Content

Support Center